Financials data is unavailable for this security.
View more
Year on year Shanghai Fosun Pharmaceutical Group Co Ltd 's revenues fell -5.85% from 43.81bn to 41.25bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 3.74bn to 2.40bn, a -35.81% decrease.
| Gross margin | 47.02% |
|---|---|
| Net profit margin | 5.97% |
| Operating margin | 3.95% |
| Return on assets | 2.11% |
|---|---|
| Return on equity | 3.98% |
| Return on investment | 3.66% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Shanghai Fosun Pharmaceutical Group Co Ltd fell by 1.67bn. However, the company earned 3.41bn from its operations for a Cash Flow Margin of 8.28%. In addition the company used 3.82bn on investing activities and also paid 1.34bn in financing cash flows.
| Cash flow per share | 2.23 |
|---|---|
| Price/Cash flow per share | 11.76 |
| Book value per share | 18.87 |
|---|---|
| Tangible book value per share | 8.18 |
More ▼
Balance sheet in CNYView more
| Current ratio | 0.9304 |
|---|---|
| Quick ratio | 0.7295 |
| Total debt/total equity | 0.7371 |
|---|---|
| Total debt/total capital | 0.3703 |
More ▼
Growth rates in CNY
SmartText is unavailable
| Div yield(5 year avg) | 1.73% |
|---|---|
| Div growth rate (5 year) | -2.91% |
| Payout ratio (TTM) | 39.24% |
| EPS growth(5 years) | -3.46 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -53.91 |
More ▼
